-
Uncategorized2 months ago
Astellas’ consolidation efforts to impact 50 Universal Cells employees
Follow along as BioSpace tracks job cuts and restructuring initiatives.
-
Uncategorized2 months agoSTAT+: Novartis CEO joins Anthropic’s board
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A reminder that...
-
Uncategorized2 months ago
Whitepaper: CDMOs at a Crossroads
In this whitepaper, BioSpace reviews the major trends impacting the CDMO sector and the evolving relationship between sponsors and providers. We examine the key qualities pharma...
-
Uncategorized2 months ago
China dominates big licensing deals as M&A starts 2026 with a bang
The start of 2026 has shaped up as an extension of the solid performance we tracked with DealForma’s Chris Dokomajilar through the second half of last...
-
Uncategorized2 months agoTrump DOJ report says Biden administration treated anti-abortion protestors unfairly
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. I was nearly late for a...
-
Uncategorized2 months ago
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs...
-
Uncategorized2 months ago
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
-
Uncategorized2 months ago
Terremoto raises $108M to make an ‘earthquake’ in small molecule space
Terremoto Biosciences has secured $108 million to fund first-in-human testing for its next-generation small molecule drugs. The South San Francisco, CA biotech, whose name translates to...
-
Uncategorized2 months agoSTAT+: New Bain biotech startup, building on BMS drugs, gets a name and a CEO
Last summer, Bain Capital Life Sciences announced that it would form a new biotech startup, created with $300 million and five drugs licensed from Bristol Myers...
-
Uncategorized2 months ago
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
Johnson and Johnson kicked off first-quarter earnings season with a “modest” beat and an ambitious goal; Replimune failed again to gain approval for its advanced melanoma...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
